14 results about "Phenylpiperazine" patented technology

Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.

The application belongs to the technical field of tertiary oil recovery, and relates to a heavy oil viscosity reducer and a preparation method and application thereof.The preparation method is as follows: p-nonyl phenol, 1-(4-fluorophenyl)piperazine, 40wt% formaldehyde and water are added into a reactor, stirring is carried out, temperature is increased to reflux, and temperature is kept;temperature is reduced to below 40 DEG C, extraction is carried out, the obtained product is placed in a high-pressure reactor, sodium hydroxide solid is added, nitrogen is introduced, vacuum is drawn, temperature is increased, vacuum drawing is stopped, ethylene oxide is slowly introduced, temperature is increased, and temperature is kept;viscous liquid is obtained through reduced pressure distillation, the obtained product is placed in a high-pressure reactor, pH is adjusted to 3-4, aminosulfonic acid powder is added, stirring and heating are carried out, temperature is kept, and the obtained product is cooled to below 40 DEG C;ethanolamine is added, pH is adjusted to 7-8, and the heavy oil viscosity reducer is obtained.The viscosity reducer has the advantages of low surface tension, low interfacial tension, low critical micelle concentration and good viscosity reduction effect.

The application relates to the technical field of new uses of medicines, and particularly discloses application of an N-phenylpiperazine derivative in preparation of a medicine for treating Parkinson's disease, wherein the N-phenylpiperazine derivative is HS. + The N-phenylpiperazine derivative HS provided by the application can significantly improve the survival rate of SH-SY5Y cells induced by MPP + , shows a dose-dependent neuroprotective effect, can effectively improve the motor dysfunction of a model animal, increase the open field movement distance, prolong the time of staying on a rotating rod, and provides a new selection for developing an anti-Parkinson's disease treatment medicine with a neuroprotective effect.

The invention relates to the technical field of fluorescent molecular materials for biological imaging, in particular to an N-phenylpiperazine fluorescent probe molecule as well as a preparation method and application thereof. The probe molecule is a fluorescent ligand receptor combined type fluorescent sensor, takes N-(2-methoxyphenyl) piperazine as a targeting group and 4-dimethylamino-1, 8-naphthalimide as a fluorescent reporter group, has specific recognition capability on a dopamine D3 receptor, and is excellent in fluorescence performance, low in cytotoxicity, fast in cell uptake (10s) and remarkable in fluorescence enhancement; the method can be used for cell imaging of mouse hippocampal nerve HT-22 cells, achieves the purpose of visualization, and has potential development value and good application prospects. The fluorescent probe is short in synthesis route, simple and easy to operate and suitable for industrial popularization and application.

The present invention discloses a phenylpiperazine-based β-carboline derivative, a preparation method and an application thereof; the phenylpiperazine-based β-carboline derivative has a structural formula shown in formula (I): #imgabs0# wherein R is one or more substituents, or R does not exist; R is independently selected from halogen, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 of halogenated alkyl, cyano, nitro, C 1～6 The present invention uses the β-carboline structure as the mother core to design and synthesize a series of phenylpiperazine-based β-carboline derivatives, which exhibit strong α-glucosidase inhibition, with an IC 50 The values ​​ranged from 4.85±0.48μM to 10.84±1.02. It can be used as an α-glucosidase inhibitor to treat and / or prevent diabetes.

The application discloses benzamide phenylpiperazine radioactive compounds and a preparation method and application thereof, and belongs to the field of radioactive drugs. 18 The F-labeled compound is simple in preparation method. The benzamide phenylpiperazine radioactive compound can be used as a dopamine D3 receptor targeted radioactive probe, and has the characteristics of excellent biological performance, high chemical purity and high specific activity.

The present invention discloses a zero-dimensional hybrid luminescent material with high-efficiency luminescent performance, its preparation method and application, and belongs to the field of solid-state light-emitting and diode display technology. Its technical scheme is as follows: the molecular formula of compound 1 is [H2MPPZ]ZnBr4; the molecular formula of compound 2 is [H2APM]ZnCl4, and the preparation steps are as follows: 1) when preparing compound 1, 1-phenylpiperazine and zinc bromide are dissolved in a mixed solution of methanol, ethylene glycol and hydrobromic acid; when preparing compound 2, N-aminopropylmorpholine and zinc chloride are dissolved in a mixed solution of methanol, ethylene glycol and hydrochloric acid; 2) the reaction vessel containing the mixed solution is sealed and placed in a constant temperature blast drying oven, the reaction is completed, filtered, washed, and dried to obtain a zero-dimensional hybrid luminescent material with high-efficiency luminescent performance. The zero-dimensional hybrid luminescent material with high-efficiency luminescent performance prepared by the present invention has high luminous intensity and good stability, and has potential applications in the fields of solid-state light-emitting and diode display.

The present application relates to the field of medicinal chemistry and pharmacotherapy, in particular to a phenylpiperazine compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof in the preparation of analgesic drugs or drugs for treating pain, wherein the phenylpiperazine compound or the pharmaceutically acceptable salt thereof has the following structure: the phenylpiperazine compound has obvious inhibitory activity on TRPV1, can obviously inhibit the pain response, and has no side effect of body temperature rise.

The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). The present description discloses the preparation of exemplary compounds (e.g. pages 37 to 45; examples 1.1 to 1.13) as well as relevant biological data thereof (e.g. pages 12 to 17, tables 1 to 9). An exemplary compound is e.g. 1-[4-(4-{1-[(6-{[6-(trifluoromethyl) pyridin-3-yl]methoxy}pyridazin-3-yl)amino]cyclopropyl}-phenyl) piperazin-1-yl]ethan-1-one (example 1.1).

The present invention provides a compound having an activation inhibitory effect on a STING pathway. Specifically, the present invention provides a phenylpiperazine derivative represented by formula (I) (in the formula, A, R1 to R8, and Q are as in the specification) or a salt thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to a small-molecule inhibitor of specific targeting ARHGAP9, a preparation method and application in tumor resistance. The invention firstly provides a novel small molecular compound N-(4-fluorobenzyl)-6-(3-phenylpiperazine-1-yl) picolinamide, the novel small molecular compound targets ARHGAP9 high-expression tumors, it is proved in anti-tumor experiments that the novel small molecular compound can effectively activate immune cells and has a good aging and dose-effect relationship, and the novel small molecular compound can be used for preparing ARHGAP9 high-expression tumors. The positive effect of resisting the growth of various transplanted tumors is achieved.

This invention relates to purine derivative G4-targeting protein chimeras, and more particularly to a class of purine derivative G4-targeting protein chimeras synthesized using PROTAC technology and possessing antitumor activity. The general structural formula of the targeting chimera is as follows: where R is a linker, representing triethylene glycol, tetraethylene glycol, pentaethylene glycol, a four-carbon chain, a five-carbon chain, a six-carbon chain, a seven-carbon chain, an eight-carbon chain, a nine-carbon chain, azacyclobutane, tetrahydropyrrole, piperidine, or 1-phenylpiperazine. Spectroscopic and mass spectrometric data analysis show that the synthesized purine derivative G4-targeting protein chimeras are novel compounds. In vitro antitumor activity studies have demonstrated that the purine derivative G4-targeting protein chimeras provided by this invention exhibit strong antitumor activity against human triple-negative breast cancer cells MDA-MB-231, human gastric adenocarcinoma cells MGC803, human liver cancer cells HepG2, and human colon cancer cells HCT-116. This is an excellent new antitumor compound with the potential to be developed into a new antitumor drug.

The invention discloses a phenylpiperazine and quinazoline hybrid compound as well as a preparation method and application thereof, belongs to the technical field of medicines, and particularly relates to an N-[2-(4-phenylpiperazine-1-yl) ethyl]-2-[(quinazoline-4-yl) amino] benzamide derivative with a structural formula as shown in a formula I and pharmaceutically acceptable salt thereof. The N-[2-(4-phenylpiperazine-1-yl) ethyl]-2-[(quinazoline-4-yl) amino] benzamide derivative or the pharmaceutically acceptable salt of the compound can be combined with an existing medicine or independently used as an influenza virus inhibitor, and has a better inhibition effect on various influenza A viruses.